Combining Ethnopharmacology and Virtual Screening for Lead Structure Discovery: COX-Inhibitors as Application Example

Virtual screening of large libraries of organic compounds combined with pharmacological high throughput screening is widely used for drug discovery in the pharmaceutical industry. Our aim was to explore the efficiency of using a biased 3D database comprising secondary metabolites from antiinflammatory medicinal plants as a source for the virtual screening. For this study pharmacophore models of cyclooxygenase I and II (COX-1, COX-2), key enzymes in the inflammation process, were generated with structure-based as well as common feature based modeling, resulting in three COX hypotheses. Four different multiconfomational 3D databases limited in molecular weight between 300 and 700 Da were applied to the screening in order to compare and analyze the obtained hit rates. Two of them were created in-house (DIOS, NPD). The database DIOS consists of 2752 compounds from phytochemical reports of antiinflammatory medicinal plants described by the ethnopharmacological source 'De material medica' of Pedanius Dioscorides, whereas NPD contains almost 80,000 compounds gathered arbitrarily from natural sources. In addition, two available multiconformational 3D libraries comprising marketed and development drug substances (DWI and NCI), mainly originating from synthesis, were used for comparison. As a test of the pharmacophore models' capability in natural sources, the models were used to search for known COX inhibitory natural products. This was achieved with some exceptions, which are discussed in the paper. Depending on the hypothesis used, DWI and NCI library searches produced hit rates in the range of 6.6% to 13.7%. A slight increase of the number of molecules assessed for binding was achieved with the database of natural products (NPD). Using the biased 3D database DIOS, however, the average increase of efficiency reached 77% to 133% compared to the hit rates resulting from WDI and NCI. The statistical benefit of a combination of an ethnopharmacological approach with the potential of computer aided drug discovery by in silico screening was demonstrated exemplified on the applied targets COX-1 and COX-2.

[1]  R. DuBois,et al.  The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. , 1995, European journal of cancer.

[2]  John M Pezzuto,et al.  Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. , 2002, Journal of natural products.

[3]  J. Pezzuto,et al.  Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. , 2003, Journal of natural products.

[4]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[5]  Y. Tezuka,et al.  Hepatoprotective constituents of the seeds of Combretum quadrangulare. , 2000, Biological & pharmaceutical bulletin.

[6]  S. Laufer,et al.  Anti-inflammatory activity of myricetin-3-O-β-D-glucuronide and related compounds , 1998, Inflammation Research.

[7]  Thierry Langer,et al.  Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. , 2003, Current opinion in drug discovery & development.

[8]  S. Fiorucci,et al.  Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  M. Filizola,et al.  Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2). , 1997, Journal of molecular graphics & modelling.

[10]  J. Pezzuto,et al.  Prenylated flavonoids of the leaves of Macaranga conifera with inhibitory activity against cyclooxygenase-2. , 2002, Phytochemistry.

[11]  Tingjun Hou,et al.  A 3D Structure Database of Components from Chinese Traditional Medicinal Herbs , 2002, J. Chem. Inf. Comput. Sci..

[12]  D. Moerman.  An analysis of the food plants and drug plants of native North America. , 1996, Journal of ethnopharmacology.

[13]  S. Sung,et al.  Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: structure-activity relationships. , 2001, Journal of natural products.

[14]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[15]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[16]  V. Steele,et al.  Strategies for identification and clinical evaluation of promising chemopreventive agents. , 1996, Oncology.

[17]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[18]  J. Pezzuto,et al.  A novel cyclooxygenase-inhibitory stilbenolignan from the seeds of Aiphanes aculeata. , 2001, Organic letters.

[19]  S. Gibbons,et al.  Ethnopharmacology in drug discovery: an analysis of its role and potential contribution , 2001, The Journal of pharmacy and pharmacology.

[20]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[21]  M. Cuendet,et al.  The Role of Cyclooxygenase and Lipoxygenase in Cancer Chemoprevention , 2000, Drug metabolism and drug interactions.

[22]  R. Flower.  The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.

[23]  H. W. Chang,et al.  Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. , 2001, Biochemical pharmacology.

[24]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage , 1995, J. Chem. Inf. Comput. Sci..

[25]  P. Kittakoop,et al.  Atropisomeric myristinins: selective COX-2 inhibitors and antifungal agents from Myristica cinnamomea. , 2002, The Journal of organic chemistry.

[26]  K U. Bindseil,et al.  Pure compound libraries; a new perspective for natural product based drug discovery. , 2001, Drug discovery today.

[27]  Hyun Pyo Kim,et al.  Effects of sophoraflavanone g, a prenylated flavonoid from sophoraFlavescens, on cyclooxygenase-2 andIn Vivo inflammatory response , 2002, Archives of pharmacal research.

[28]  B. Cryer,et al.  The advent of highly selective inhibitors of cyclooxygenase--a review. , 1998, Prostaglandins & other lipid mediators.

[29]  K. Koike.  Role of hepatitis viruses in multistep hepatocarcinogenesis. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[30]  V. Goldberg,et al.  Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. , 2002, Free radical biology & medicine.

[31]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[32]  M. Nair,et al.  Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. , 2000, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[33]  J. Wallace,et al.  Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. , 2002, Gastroenterology.

[34]  J. Pezzuto,et al.  Cancer Chemopreventive Agents Discovered by Activity-Guided Fractionation: An Update , 2003 .

[35]  M. Hamburger,et al.  Identification and isolation of the cyclooxygenase-2 inhibitory principle in Isatis tinctoria. , 2001, Planta medica.

[36]  H. Bartsch,et al.  Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. , 2002, Molecular cancer therapeutics.

[37]  J. Pezzuto,et al.  Two new stilbene dimer glucosides from grape (Vitis vinifera) cell cultures. , 2001, Journal of natural products.

[38]  A. Kiderlen,et al.  Abietane diterpenoids and triterpenoic acids from Salvia cilicica and their antileishmanial activities. , 2002, Phytochemistry.

[39]  G. Valacchi,et al.  Inhibition of TNFα-induced cyclooxygenase-2 expression by amentoflavone through suppression of NF-κB activation in A549 cells , 2002, Molecular and Cellular Biochemistry.

[40]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[41]  G. Levy.  Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  M. Hamburger,et al.  Quantitative determination of the dual COX-2/5-LOX inhibitor tryptanthrin in Isatis tinctoria by ESI-LC-MS. , 2002, Planta medica.

[43]  C. Christophersen.  Evolution in molecular structure and adaptive variance in metabolism. , 1991, Comparative biochemistry and physiology. B, Comparative biochemistry.

[44]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[45]  K. Likhitwitayawuid,et al.  Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri. , 2002, Planta Medica.

[46]  F. Hadacek.  Secondary Metabolites as Plant Traits: Current Assessment and Future Perspectives , 2002 .

[47]  T. Scior,et al.  Ethnopharmacology and bioinformatic combination for leads discovery: application to phospholipase A(2) inhibitors. , 2001, Phytochemistry.

[48]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.